RT Book, Section
A1 Wo, Jennifer
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127649103
T1 Anal Cancer
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127649103
RD 2024/04/20
AB Anal  cancer  is  responsible  for  approximately  2.1%  of  digestive  system  malignancies  with  6230  new  cases  estimated  in  the  United  States  in  2012  (1).  Anal  cancer  was  once  believed  to  be  caused  by  chronic  inflammation  of  the  anal  canal  and  treated  with  abdominoperineal  resection  (APR).  Research  has  now  shown  that  the  development  of  anal  cancer  is  associated  with  human  papillomavirus  (HPV)  infection  and  has  a  pathophysiology  similar  to  that  of  cervical  cancer.  Concurrent  chemotherapy  and  external  beam  radiation  therapy  (EBRT)  regimens  have  essentially  replaced  APR  as  primary  treatment  and  have  allowed  for  a  great  majority  of  patients  to  be  cured  with  preservation  of  the  anal  sphincter.